Tuesday, AngioDynamics Inc (NASDAQ: ANGO) reported a fourth-quarter 2024 adjusted EPS loss of $0.05, compared to the consensus loss of $0.16. Fourth-quarter sales totaled $70.98 million, beating the analyst consensus of $70.89 million, according to data from Benzinga Pro. Pro forma net sales rose 1.9% to $71.1 million. Med Tech segment net sales were $29.3 million, up 11.3% year over year. Growth was driven by Auryon sales of $13.0 million, which increased 12.0%, NanoKnife disposable sales of $5.4 million, representing an increase of 18.0% compared to the fourth quarter of fiscal 2023, and AlphaVac sales of $1.9 million, an increase of 6.8% over the prior year. Med Device net sales were $41.8 million, a ...